Central nervous system involvement in adult acute lymphoblastic leukemia

References

• Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997; 99: 84–92.
   PubMed Web of Science ®Google Scholar
• Fiere D, Lepage E, Sebban C et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11: 1990–2001.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Ludwig WD et al. Follow-up of the first twosuccessive German multicentre trials for adult ALL (01/81 and 02/ 84). Leukemia 1993; 7 (Suppl. 2): S130–S134.
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995; 85: 2025–2037.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Annino L, Rotoli B. The GIMEMA ALL 0183 trial,analysis of 10-year follow-up. Br J Haematol 1996; 92: 663–672.
   Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith TL et al. Results of treatmentwith Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F et al. Outcome of treatment inadults with acute lymphoblastic leukemia: Analysis of LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK et al. Induction therapy for adultswith acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ ECOG E2993. Blood 2005; 106: 3760–3767.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Löffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien SM, Pierce S et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995; 86: 2091–2097.
   PubMed Web of Science ®Google Scholar
• Reman O, Pigneux A, Huguet F et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res 2008; 32: 1741–1750.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Richards SM, Chopra M et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006; 108: 465–472.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Keating MJ, McCredie KB et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981; 47: 184–196.
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Eppinger-Helft M, Sackmann MF. Factors that influence the appearance of central nervous system leukemia. Blood 1973; 42: 935–938.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495–508.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O'Brien S et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461–2470.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Walters RS, Smith TL et al. Identification of risk groups for development of central nervous system leukemia. Blood 1988; 72: 1784–1789.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Smith TL, Estey E et al. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lympho-cytic leukemia. Am J Med 1992; 93: 599–604.
   PubMed Web of Science ®Google Scholar
• Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 145–162.
   PubMed Web of Science ®Google Scholar
• Mahmoud HH, Rivera GK, Hancock ML et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993; 329: 314–319
   PubMed Web of Science ®Google Scholar
• Mastrangelo R, Poplack D, Bleyer A et al. Report and recommendations of the Rome workshop concerning poor-prog-nosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986; 14: 191–194.
   PubMedGoogle Scholar
• Mavlight GM, Stuckey SE, Cabanillas FF et al. Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med 1980; 303: 718–722.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Evers LM, Dellemijn PL et al. Elevation of cerebrospinal fluid soluble CD27 in patients with meningeal localization of lymphoid malignancies. Blood 1996; 87: 1985–1989.
   PubMed Web of Science ®Google Scholar
• Januskiewicz DA, Nowak JS. Molecular evidence for central nervous system involvement in children with newly diagnosed acute lymphoblastic leukemia. Hematol Oncol 1995; 13: 201–206.
   PubMed Web of Science ®Google Scholar
• Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992; 30: 251–260.
   Google Scholar
• Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25: 2295–2305.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien JP, Boccia D et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–1287.
   PubMed Web of Science ®Google Scholar
• Dukic SF, Heurtaux T, Kaltenbach ML et al. Influence of scheduleof administration on methotrexate penetration in brain tumors. Eur J Cancer 2000; 36: 1578–1584.
   PubMed Web of Science ®Google Scholar
• Iacoangeli M, Roselli R, Pagano L et al. Intrathecal chemotherapy for treatment of overt meningeal leukemia: comparison between intraventricular and traditional intralumbar route. Ann Oncol 1995; 6: 377–382.
   PubMed Web of Science ®Google Scholar
• Schauer P, Arlin ZA, Mertelsmann R et al. Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462–470.
   PubMed Web of Science ®Google Scholar
• Johanson CE. The choroid plexus-CSF nexus: gateway to the brain. In: Conn PM. (ed) Neuroscience in medicine. Totowa, Ni: Humana Press, 2003; 165-195.
   Google Scholar
• Siegler BI, Kennedy K, Maze R et al. Comparison of long-term neurocognitive outcomes in young children with acute lympho-blastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 2006; 24: 3858–3864.
   PubMed Web of Science ®Google Scholar
• Hill FG, Richards S, Gibson B et al. Successful treatment without cranial radiotherapy of children receiving intensified chemother-apy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33–46.
   PubMed Web of Science ®Google Scholar
• Rueda Dominguez A, Olmos Hidalgo D, Viciana Garrido R et al. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Trans/ Oncol 2005; 7: 232–238.
   PubMedGoogle Scholar
• Tsuchiya J, Motecki M, Shimano S et al. Proliferation kinetics of leukemic cells in meningeal leukemia. Cancer (Phila.) 1978; 42: 1255–1242.
   PubMed Web of Science ®Google Scholar
• Blasberg R, Fenstermacher J, Levin V et al. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfu-sion. J Pharmacol Exp Ther 1975; 195: 73–83.
   PubMed Web of Science ®Google Scholar
• Sullivan M, Moon T, Trueworthy R et al. Combination intrathecal therapy for meningeal leukemia: two versus three drugs. Blood 1977; 50: 471–479.
   PubMed Web of Science ®Google Scholar
• Chabner BA. Cytidine analogues. In: Chabner BA, Longo DL. (eds) Cancer chemotherapy and biotherapy: principles and practice, 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996; 213-233.
   Google Scholar
• Glantz MJ, Jaeckle KA, Chamberlain MD et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with meningitis from solid tumors. Clin Cancer Res 1999; 5: 3394–3402.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim DJ, Geyer MA et al. Multivesicular liposomes containing 1-B-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res 1987; 47: 3935–3937.
   PubMed Web of Science ®Google Scholar
• Kim S, Khatibi S, Howell SB et al. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 1993; 53: 1596–1598.
   PubMed Web of Science ®Google Scholar
• Zimm S, Collins JM, Miser J et al. 1-β-D-arabinofuranosylcytosinecerebrospinal fluid kinetics. Clin Pharmacol Ther 1984; 35: 826–830.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Schaeverbeke T, Pehourcq F et al. Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Rev Rhum 1997; 64: 301–304.
   PubMedGoogle Scholar
• Balis FM, Lester CM, Chrousos GP et al. Differences in cerebrospinal fluid penetration of corticosteroids: Possible rela-tionship to the prevention of meningeal leukemia. J Clin Oncol 1987; 5: 202–207.
   PubMed Web of Science ®Google Scholar
• Jones B, Freeman AT, Shuster ii, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexametha-sone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991; 19: 269–275.
   PubMedGoogle Scholar
• Morra E, Lazzarino M, Inverdadi D et al. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Clin Oncol 1986; 4: 1207–1211.
   PubMed Web of Science ®Google Scholar
• Gi5kbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neuro Oncol 1998; 38: 167–180.
   PubMed Web of Science ®Google Scholar
• Morra E, Lazzarino M, Brusamolino E et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia: clinical results in 46 patients. Cancer 1993; 72: 439–445.
   PubMed Web of Science ®Google Scholar
• Balis FM, Savitch JL, Bleyer WA et al. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985; 3: 485–489.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499–505.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Head DR et al. Comparison of the Li OM consolidation regimen including escalating methotrexate/L-asparaginase for aduld acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia 2001; 15: 208–216.
   PubMed Web of Science ®Google Scholar
• Linker CA, Levitt Li, O'Donnell M et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78: 2814–2822.
   PubMed Web of Science ®Google Scholar
• Gururangan S, Sposto R, Cairo MS et al. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol 2000; 18: 2017–2025.
   PubMed Web of Science ®Google Scholar
• Wen PY. Central nervous system complications of cancer therapy. In: Schiff D, Wen PY. (eds) Cancer neurology in clinical practice. Totowa, Ni: Humana Press, 2003; 215-231.
   Google Scholar
• Yim YS, Mahoney DH, Jr, Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991; 67: 2058–2061.
   PubMed Web of Science ®Google Scholar
• Walker RW, Allen JC, Rosen G et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986; 4: 1845–1850.
   PubMed Web of Science ®Google Scholar
• Ochs J, Mulhern R, Fairclough D et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxi-city in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Chin Oncol 1991; 9: 145–151.
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Poplack DG, Bleyer WA. Neurotoxicities of current leukaemia therapy. Am J Pediatr Hematol Oncol 1979; 1: 127–140.
   PubMedGoogle Scholar
• Neuwelt EA, Guastadisegni PE, Varallyay Pet al. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 2005; 26: 258–265.
   PubMed Web of Science ®Google Scholar
• Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005; 64: 1184–1188.
   PubMed Web of Science ®Google Scholar
• Cohen U. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphocytic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 2004; 26: 156–163.
   PubMed Web of Science ®Google Scholar
• Herzig RH, Hines JD, Herzig GP et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987; 5: 927–932.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O'Brien S, Kantarjian H et al. Neurologic complica-tions associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 109: 3214–3218.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz Mi. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylac-tically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 110: 1698.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Jabbour E, Kantarjian H et al. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen. Blood 2007; 110: 1698–1699.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Porto L, Lanfermann H et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lympho-blastic leukemia. J Pediatr Hematol Oncol 2003; 25: 484–487.
   PubMed Web of Science ®Google Scholar
• Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 2000; 22: 111–122.
   PubMed Web of Science ®Google Scholar
• Nelson DA. Intraspinal therapy using methylprenisolone acetate. Twenty-three years of clinical controversy. Spine 1993; 18: 278–286.
   PubMed Web of Science ®Google Scholar
• Meanwell CA, Blake AE, Kelly KA et al. Prediction of ifosfamide/ mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815–819.
   PubMedGoogle Scholar
• van Vulpen M, Kal HB, Taph000rn MJ et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 2002; 9: 683–688.
   PubMed Web of Science ®Google Scholar
• Schiff D, Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin N Am 2006; 20: 1377–1398.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Le QH, de Botton S, et al. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer 2007; 110: 2747–2755
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Poplack DA. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985; 12: 131–148.
   PubMed Web of Science ®Google Scholar
• Omura GA, Moffitt S, Vogler WR et al. Combination chemother-apy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980; 55: 199–204.
   PubMed Web of Science ®Google Scholar
• Blaney SM, Balis FM, Poplack DG. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs 1991; 41: 702–716.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL et al. L-asparaginase pharmacokinetics and asparaginase levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981; 41: 4554–4558.
   PubMed Web of Science ®Google Scholar
• Ito C, Evans WE, McNinch L et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 2370–2376.
   PubMed Web of Science ®Google Scholar
• Relling MV, Mahmoud HH, Pui CH et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 399–404.
   PubMed Web of Science ®Google Scholar
• Zimm S, Ettinger Li, Holcenberg JS et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985; 45: 1869–1873.
   PubMed Web of Science ®Google Scholar
• Hussein KK, Dahlberg S, Head D et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57–63.
   PubMed Web of Science ®Google Scholar
• Kamps WA, Bokkerink JP, Hahlen K et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999; 94: 1226–1236.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Dutcher JP, Paietta E et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia 1993; 7: 1236–1241.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lhéritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780.
   PubMed Web of Science ®Google Scholar
• Huguet F, Raffoux E, Thomas X, et al. Towards a pediatric approach in adults with acute lymphoblastic leukemia (ALL): the GRAALL-2003 study. Blood 2006; 108 (Suppl. 1): 48a.
   Google Scholar
• Radford JE Jr, Burns CP, Jones MP, et al. Adult acute lymphoblastic leukemia: Results of the Iowa HOP-L protocol. J Clin Oncol 1989; 7: 58–66.
   PubMed Web of Science ®Google Scholar
• Surapaneni UR, Cortes JE, Thomas D et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002; 94: 773–779.
   PubMed Web of Science ®Google Scholar
• Neale GA, Pui CH, Mahmoud HH et al. Molecular evidence for minimal residual bone marrow disease in children with "isolated" extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 1994; 8: 768–775.
   PubMed Web of Science ®Google Scholar
• Goulden N, Langlands K, Stewart C et al. PCR assessment of bone marrow status in "isolated" extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J haematol 1994; 87: 282–285.
   PubMed Web of Science ®Google Scholar
• Lawson SE, Harrison G, Richards S et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol 2000; 108: 531–543.
   PubMed Web of Science ®Google Scholar
• Barredo JC, Devidas M, Lauer Si et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol 2006; 24: 3142–3149.
   PubMed Web of Science ®Google Scholar
• Gi5kbuget N, Arnold R, Buchner T et al. Treatment of adult acute lymphoblastic leukemia. Schweiz Rundsch Med Prax 1999; 88:407–420.
   Google Scholar
• Tavernier E, Boiron JM, Huguet F et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907–1914.
   PubMed Web of Science ®Google Scholar
• Arnold R, Massenkeil G, Bornhauser M et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002; 16: 2423–2428.
   PubMed Web of Science ®Google Scholar
• Ritchey AK, Pollock BH, Lauer Si et al. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1999; 17: 3745–3752.
   PubMed Web of Science ®Google Scholar